Abstract Number: 1326 • ACR Convergence 2020
Malignancy Risk Among Patients with Ankylosing Spondylitis in the United States: A Population-Based National Study
Background/Purpose: Increased cancer risk has been reported with Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), but the correlation is poorly studied in Ankylosing spondylitis…Abstract Number: 1332 • ACR Convergence 2020
Identifying the as Patient at Risk: Is Aortic Root Diameter Associated with HLA-B27?
Background/Purpose: Ankylosing spondylitis (AS) is an inflammatory joint disease (IJD) associated with cardiac involvement particularly aortic valve regurgitation (AVR). AVR in AS is caused by…Abstract Number: 1331 • ACR Convergence 2020
Carotid Ultrasound Findings in Psoriatic Arthritis: A Case-control Study
Background/Purpose: Patients with psoriatic arthritis (PsA) have an increased risk of cardiovascular disease (CVD). The carotid ultrasound, which measures both carotid intima-media thickness (cIMT) and…Abstract Number: 1337 • ACR Convergence 2020
Relationship of the Pro12Ala Polymorphism of the PPARg Gene with Inflammatory Activity, Osteoporosis and Obesity in Patients with Psoriatic Arthritis
Background/Purpose: In the pathogenesis of psoriatic arthritis (PsA), increased inflammatory cytokines lead to increased RANGO-L activity and stimulation of osteoclasts, leading to osteoporosis. This comorbidity,…Abstract Number: 1339 • ACR Convergence 2020
COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Background/Purpose: The COVID-19 pandemic has quickly emerged as the most challenging global health crisis in a generation. Affecting initially China, New York City (NYC) quickly…Abstract Number: 1334 • ACR Convergence 2020
Does Interstitial Lung Disease Represent a Real Comorbidity in Spondyloarthritis Patients? Results from an Ultrasound, Monocentric, Pilot Study
Background/Purpose: Background: Interstitial lung disease (ILD) is a frequent complication in rheumatoid arthritis (RA) where it represents the most common extra-articular involvement (with a prevalence…Abstract Number: 1329 • ACR Convergence 2020
Subclinical Atherosclerosis Risk in Psoriatic Arthritis: Could It Be Prevented?
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthritis associated with psoriasis that can cause remarkable joint damage (1). Subclinical cardiovascular disease (CVD) due to…Abstract Number: 1342 • ACR Convergence 2020
Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK
Background/Purpose: Etanercept (ETN) is effective and well tolerated in patients with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is limited information on the effects of withdrawing…Abstract Number: 1345 • ACR Convergence 2020
Upadacitinib as Monotherapy and in Combination with Non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Analysis from Two Phase 3 Trials
Background/Purpose: Approximately 40% of PsA patients (pts) on advanced therapy are on monotherapy.1,2 Upadacitinib (UPA) has shown efficacy and safety in pts with active PsA…Abstract Number: 1346 • ACR Convergence 2020
Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis
Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous. In clinical practice, both patients and…Abstract Number: 1341 • ACR Convergence 2020
Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study
Background/Purpose: Patient-reported outcomes (PROs) are important when evaluating treatment benefits in PsA. We present an analysis of PRO data from the SELECT-PsA 1 study.Methods: SELECT-PsA…Abstract Number: 1352 • ACR Convergence 2020
Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes over…Abstract Number: 1349 • ACR Convergence 2020
Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody that specifically binds to the p19-subunit of IL-23. GUS has demonstrated efficacy across the various manifestations of…Abstract Number: 1344 • ACR Convergence 2020
Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced
Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19-subunit of IL-23, is approved to treat psoriasis (PsO). At Week 24 of the…Abstract Number: 1236 • ACR Convergence 2020
Association Between Change in Health Assessment Questionnaire Disability Index and Treatment Response in Patients with Rheumatoid Arthritis in Tocilizumab Clinical Trials
Background/Purpose: The efficacy and safety of intravenous (IV) and subcutaneous (SC) tocilizumab (TCZ) in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and as monotherapy…
- « Previous Page
- 1
- …
- 714
- 715
- 716
- 717
- 718
- …
- 2425
- Next Page »